Share Price and Basic Stock Data
Last Updated: January 12, 2026, 4:27 pm
| PEG Ratio | -0.75 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Hemant Surgical Industries Ltd operates within the medical equipment and accessories sector, focusing on delivering innovative solutions for healthcare. The company reported sales of ₹109 Cr for the fiscal year ending March 2023, which slightly declined to ₹106 Cr in March 2024, and is expected to stabilize around ₹107 Cr for the fiscal year 2025. Historically, sales have shown a progressive increase from ₹51 Cr in March 2018 to ₹101 Cr in March 2022, indicating a compound annual growth rate (CAGR) of approximately 36.7% over this five-year span. Quarterly sales data reveals fluctuations, with a peak of ₹58 Cr in March 2023 and a dip to ₹48 Cr in September 2023, which suggests the company’s revenue is sensitive to market conditions and operational challenges. The trailing twelve months (TTM) sales stood at ₹122 Cr, reflecting resilience amidst demand variability.
Profitability and Efficiency Metrics
The profitability of Hemant Surgical Industries is underscored by its robust operating profit margin (OPM), which stood at 10.5% for the trailing twelve months. The company reported a net profit of ₹8 Cr for the fiscal year 2023, with a net profit margin of 7.54%. This is a notable improvement from ₹1 Cr in March 2018, illustrating significant growth in profitability over the years. The return on equity (ROE) is reported at 13.6%, while return on capital employed (ROCE) is at 16.4%, indicating effective utilization of equity and capital. However, the cash conversion cycle has deteriorated to 87 days in September 2023, suggesting challenges in managing inventory and receivables, which could impact liquidity. The interest coverage ratio (ICR) of 6.40x indicates that the company can comfortably meet its interest obligations, a positive aspect in terms of financial health.
Balance Sheet Strength and Financial Ratios
As of March 2025, Hemant Surgical Industries reported total assets of ₹214 Cr, with total liabilities amounting to ₹148 Cr, resulting in a debt-to-equity ratio of 0.49. This indicates a moderate level of leverage, which is manageable given the company’s interest coverage ratio. The company’s reserves have seen substantial growth, increasing from ₹16 Cr in March 2023 to ₹110 Cr by September 2025, showcasing a strong retention of earnings. The current ratio is reported at 1.45, suggesting adequate liquidity to cover short-term obligations. Furthermore, the price-to-book value (P/BV) ratio of 1.65x indicates that the stock is trading at a premium relative to its book value, reflecting investor confidence in the company’s growth prospects. However, the high P/E ratio of 34.9 suggests that the stock may be overvalued compared to industry peers.
Shareholding Pattern and Investor Confidence
The shareholding structure of Hemant Surgical Industries reveals a significant promoter holding of 58.90% as of September 2025, indicating strong control by the founding members. Foreign institutional investors (FIIs) have a negligible stake of 0.15%, while domestic institutional investors (DIIs) hold 10.81%, reflecting moderate interest from institutional players. Public shareholding has increased to 30.13%, showing growing confidence among retail investors. The total number of shareholders has declined to 758, down from 1,229 in March 2025, which may indicate a consolidation phase or a lack of interest from smaller investors. The company’s ability to maintain promoter stakes while attracting institutional investments may enhance its credibility and stability in the market, fostering a positive outlook for future capital raising and strategic initiatives.
Outlook, Risks, and Final Insight
Looking ahead, Hemant Surgical Industries faces both opportunities and risks. The company’s strong growth in reserves and manageable debt levels are significant strengths, indicating a solid foundation for expansion. However, the declining sales figures in recent quarters, coupled with an increasing cash conversion cycle, pose risks to liquidity and operational efficiency. Moreover, the fluctuating profit margins highlight the need for improved cost management strategies. The company could benefit from diversifying its product offerings or enhancing its operational capabilities to mitigate these risks. If managed effectively, the company has the potential to leverage its established market position and financial strength to navigate the competitive landscape of the medical equipment sector successfully. Conversely, failure to address these operational challenges may impact its growth trajectory and investor confidence.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Hemant Surgical Industries Ltd | 378 Cr. | 290 | 367/88.2 | 36.5 | 94.3 | 0.00 % | 16.4 % | 13.6 % | 10.0 |
| Industry Average | 378.00 Cr | 290.00 | 36.50 | 94.30 | 0.00% | 16.40% | 13.60% | 10.00 |
Quarterly Result
| Metric | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|
| Sales | 51 | 58 | 48 | 58 | 49 | 58 | 64 |
| Expenses | 47 | 52 | 44 | 51 | 45 | 52 | 57 |
| Operating Profit | 4 | 6 | 3 | 7 | 4 | 6 | 8 |
| OPM % | 8% | 11% | 7% | 13% | 7% | 10% | 12% |
| Other Income | 1 | 1 | 3 | 2 | 2 | 3 | 2 |
| Interest | 1 | 1 | 1 | 0 | 1 | 1 | 2 |
| Depreciation | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 4 | 6 | 5 | 8 | 4 | 6 | 7 |
| Tax % | 36% | 18% | 17% | 27% | 29% | 18% | 25% |
| Net Profit | 2 | 5 | 4 | 6 | 3 | 5 | 5 |
| EPS in Rs | 48.12 | 6.93 | 3.75 | 5.63 | 3.05 | 4.74 | 4.15 |
Last Updated: January 1, 2026, 10:16 am
Below is a detailed analysis of the quarterly data for Hemant Surgical Industries Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 64.00 Cr.. The value appears strong and on an upward trend. It has increased from 58.00 Cr. (Mar 2025) to 64.00 Cr., marking an increase of 6.00 Cr..
- For Expenses, as of Sep 2025, the value is 57.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 52.00 Cr. (Mar 2025) to 57.00 Cr., marking an increase of 5.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 8.00 Cr.. The value appears strong and on an upward trend. It has increased from 6.00 Cr. (Mar 2025) to 8.00 Cr., marking an increase of 2.00 Cr..
- For OPM %, as of Sep 2025, the value is 12.00%. The value appears strong and on an upward trend. It has increased from 10.00% (Mar 2025) to 12.00%, marking an increase of 2.00%.
- For Other Income, as of Sep 2025, the value is 2.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3.00 Cr. (Mar 2025) to 2.00 Cr., marking a decrease of 1.00 Cr..
- For Interest, as of Sep 2025, the value is 2.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.00 Cr. (Mar 2025) to 2.00 Cr., marking an increase of 1.00 Cr..
- For Depreciation, as of Sep 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 7.00 Cr.. The value appears strong and on an upward trend. It has increased from 6.00 Cr. (Mar 2025) to 7.00 Cr., marking an increase of 1.00 Cr..
- For Tax %, as of Sep 2025, the value is 25.00%. The value appears to be increasing, which may not be favorable. It has increased from 18.00% (Mar 2025) to 25.00%, marking an increase of 7.00%.
- For Net Profit, as of Sep 2025, the value is 5.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 5.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 4.15. The value appears to be declining and may need further review. It has decreased from 4.74 (Mar 2025) to 4.15, marking a decrease of 0.59.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:14 am
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 51 | 56 | 56 | 60 | 101 | 109 | 106 | 107 | 122 |
| Expenses | 48 | 53 | 53 | 57 | 95 | 98 | 95 | 97 | 109 |
| Operating Profit | 2 | 3 | 3 | 3 | 6 | 11 | 10 | 9 | 13 |
| OPM % | 5% | 5% | 5% | 5% | 6% | 10% | 10% | 9% | 11% |
| Other Income | 0 | 0 | 0 | 1 | 2 | 2 | 4 | 5 | 5 |
| Interest | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 2 | 3 |
| Depreciation | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 1 | 1 | 1 | 1 | 6 | 10 | 13 | 11 | 13 |
| Tax % | 10% | 8% | 41% | 9% | 25% | 24% | 23% | 23% | |
| Net Profit | 1 | 1 | 0 | 1 | 5 | 8 | 10 | 8 | 10 |
| EPS in Rs | 50.76 | 61.02 | 27.00 | 73.43 | 248.92 | 9.95 | 9.39 | 7.79 | 8.89 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2018-2019 | 2019-2020 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | -100.00% | 400.00% | 60.00% | 25.00% | -20.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | -100.00% | 500.00% | -340.00% | -35.00% | -45.00% |
Hemant Surgical Industries Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 6 years from 2018-2019 to 2024-2025.
Growth
Last Updated: September 5, 2025, 6:30 am
Balance Sheet
Last Updated: December 10, 2025, 2:49 am
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 2 | 2 | 8 | 10 | 10 | 13 |
| Reserves | 5 | 6 | 5 | 8 | 11 | 16 | 44 | 53 | 110 |
| Borrowings | 9 | 11 | 14 | 14 | 10 | 7 | 7 | 31 | 53 |
| Other Liabilities | 12 | 14 | 23 | 15 | 32 | 34 | 38 | 54 | 39 |
| Total Liabilities | 28 | 33 | 44 | 40 | 54 | 65 | 100 | 148 | 214 |
| Fixed Assets | 7 | 8 | 10 | 11 | 12 | 13 | 18 | 40 | 34 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 17 |
| Investments | 0 | 0 | 1 | 0 | 1 | 0 | 5 | 1 | 3 |
| Other Assets | 21 | 25 | 33 | 29 | 42 | 51 | 77 | 94 | 160 |
| Total Assets | 28 | 33 | 44 | 40 | 54 | 65 | 100 | 148 | 214 |
Below is a detailed analysis of the balance sheet data for Hemant Surgical Industries Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 13.00 Cr.. The value appears strong and on an upward trend. It has increased from 10.00 Cr. (Mar 2025) to 13.00 Cr., marking an increase of 3.00 Cr..
- For Reserves, as of Sep 2025, the value is 110.00 Cr.. The value appears strong and on an upward trend. It has increased from 53.00 Cr. (Mar 2025) to 110.00 Cr., marking an increase of 57.00 Cr..
- For Borrowings, as of Sep 2025, the value is 53.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 31.00 Cr. (Mar 2025) to 53.00 Cr., marking an increase of 22.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 39.00 Cr.. The value appears to be improving (decreasing). It has decreased from 54.00 Cr. (Mar 2025) to 39.00 Cr., marking a decrease of 15.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 214.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 148.00 Cr. (Mar 2025) to 214.00 Cr., marking an increase of 66.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 34.00 Cr.. The value appears to be declining and may need further review. It has decreased from 40.00 Cr. (Mar 2025) to 34.00 Cr., marking a decrease of 6.00 Cr..
- For CWIP, as of Sep 2025, the value is 17.00 Cr.. The value appears strong and on an upward trend. It has increased from 12.00 Cr. (Mar 2025) to 17.00 Cr., marking an increase of 5.00 Cr..
- For Investments, as of Sep 2025, the value is 3.00 Cr.. The value appears strong and on an upward trend. It has increased from 1.00 Cr. (Mar 2025) to 3.00 Cr., marking an increase of 2.00 Cr..
- For Other Assets, as of Sep 2025, the value is 160.00 Cr.. The value appears strong and on an upward trend. It has increased from 94.00 Cr. (Mar 2025) to 160.00 Cr., marking an increase of 66.00 Cr..
- For Total Assets, as of Sep 2025, the value is 214.00 Cr.. The value appears strong and on an upward trend. It has increased from 148.00 Cr. (Mar 2025) to 214.00 Cr., marking an increase of 66.00 Cr..
Notably, the Reserves (110.00 Cr.) exceed the Borrowings (53.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -7.00 | -8.00 | -11.00 | -11.00 | -4.00 | 4.00 | 3.00 | -22.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 35 | 36 | 35 | 26 | 56 | 58 | 75 | 70 |
| Inventory Days | 64 | 73 | 125 | 113 | 57 | 67 | 99 | 205 |
| Days Payable | 102 | 97 | 143 | 89 | 92 | 110 | 116 | 188 |
| Cash Conversion Cycle | -3 | 12 | 17 | 51 | 21 | 15 | 58 | 87 |
| Working Capital Days | 12 | 23 | -28 | 41 | -19 | 2 | 52 | 61 |
| ROCE % | 15% | 12% | 14% | 32% | 45% | 30% | 16% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 |
|---|---|
| FaceValue | 10.00 |
| Basic EPS (Rs.) | 7.70 |
| Diluted EPS (Rs.) | 7.70 |
| Cash EPS (Rs.) | 9.07 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 60.51 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 60.51 |
| Revenue From Operations / Share (Rs.) | 102.14 |
| PBDIT / Share (Rs.) | 13.50 |
| PBIT / Share (Rs.) | 12.14 |
| PBT / Share (Rs.) | 10.02 |
| Net Profit / Share (Rs.) | 7.70 |
| NP After MI And SOA / Share (Rs.) | 7.70 |
| PBDIT Margin (%) | 13.21 |
| PBIT Margin (%) | 11.88 |
| PBT Margin (%) | 9.81 |
| Net Profit Margin (%) | 7.54 |
| NP After MI And SOA Margin (%) | 7.54 |
| Return on Networth / Equity (%) | 12.72 |
| Return on Capital Employeed (%) | 14.55 |
| Return On Assets (%) | 5.42 |
| Long Term Debt / Equity (X) | 0.36 |
| Total Debt / Equity (X) | 0.49 |
| Current Ratio (X) | 1.45 |
| Quick Ratio (X) | 0.74 |
| Interest Coverage Ratio (X) | 6.40 |
| Interest Coverage Ratio (Post Tax) (X) | 4.65 |
| Enterprise Value (Cr.) | 125.52 |
| EV / Net Operating Revenue (X) | 1.18 |
| EV / EBITDA (X) | 8.90 |
| MarketCap / Net Operating Revenue (X) | 0.97 |
| Price / BV (X) | 1.65 |
| Price / Net Operating Revenue (X) | 0.97 |
| EarningsYield | 0.07 |
After reviewing the key financial ratios for Hemant Surgical Industries Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. No previous period data is available for comparison.
- For Basic EPS (Rs.), as of Mar 25, the value is 7.70. This value is within the healthy range. No previous period data is available for comparison.
- For Diluted EPS (Rs.), as of Mar 25, the value is 7.70. This value is within the healthy range. No previous period data is available for comparison.
- For Cash EPS (Rs.), as of Mar 25, the value is 9.07. This value is within the healthy range. No previous period data is available for comparison.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 60.51. No previous period data is available for comparison.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 60.51. No previous period data is available for comparison.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 102.14. No previous period data is available for comparison.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 13.50. This value is within the healthy range. No previous period data is available for comparison.
- For PBIT / Share (Rs.), as of Mar 25, the value is 12.14. This value is within the healthy range. No previous period data is available for comparison.
- For PBT / Share (Rs.), as of Mar 25, the value is 10.02. This value is within the healthy range. No previous period data is available for comparison.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 7.70. This value is within the healthy range. No previous period data is available for comparison.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 7.70. This value is within the healthy range. No previous period data is available for comparison.
- For PBDIT Margin (%), as of Mar 25, the value is 13.21. This value is within the healthy range. No previous period data is available for comparison.
- For PBIT Margin (%), as of Mar 25, the value is 11.88. This value is within the healthy range. No previous period data is available for comparison.
- For PBT Margin (%), as of Mar 25, the value is 9.81. This value is below the healthy minimum of 10. No previous period data is available for comparison.
- For Net Profit Margin (%), as of Mar 25, the value is 7.54. This value is within the healthy range. No previous period data is available for comparison.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 7.54. This value is below the healthy minimum of 8. No previous period data is available for comparison.
- For Return on Networth / Equity (%), as of Mar 25, the value is 12.72. This value is below the healthy minimum of 15. No previous period data is available for comparison.
- For Return on Capital Employeed (%), as of Mar 25, the value is 14.55. This value is within the healthy range. No previous period data is available for comparison.
- For Return On Assets (%), as of Mar 25, the value is 5.42. This value is within the healthy range. No previous period data is available for comparison.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.36. This value is within the healthy range. No previous period data is available for comparison.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.49. This value is within the healthy range. No previous period data is available for comparison.
- For Current Ratio (X), as of Mar 25, the value is 1.45. This value is below the healthy minimum of 1.5. No previous period data is available for comparison.
- For Quick Ratio (X), as of Mar 25, the value is 0.74. This value is below the healthy minimum of 1. No previous period data is available for comparison.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 6.40. This value is within the healthy range. No previous period data is available for comparison.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 4.65. This value is within the healthy range. No previous period data is available for comparison.
- For Enterprise Value (Cr.), as of Mar 25, the value is 125.52. No previous period data is available for comparison.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.18. This value is within the healthy range. No previous period data is available for comparison.
- For EV / EBITDA (X), as of Mar 25, the value is 8.90. This value is within the healthy range. No previous period data is available for comparison.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.97. This value is below the healthy minimum of 1. No previous period data is available for comparison.
- For Price / BV (X), as of Mar 25, the value is 1.65. This value is within the healthy range. No previous period data is available for comparison.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.97. This value is below the healthy minimum of 1. No previous period data is available for comparison.
- For EarningsYield, as of Mar 25, the value is 0.07. This value is below the healthy minimum of 5. No previous period data is available for comparison.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Hemant Surgical Industries Ltd:
- Net Profit Margin: 7.54%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 14.55% (Industry Average ROCE: 16.4%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 12.72% (Industry Average ROE: 13.6%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 4.65
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.74
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 36.5 (Industry average Stock P/E: 36.5)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.49
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 7.54%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Medical Equipment & Accessories | 502, 5th Floor, Ecstasy Business Park Co-Op Socteiy Limited, Mumbai Maharashtra 400080 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Hanskumar Shah | Chairman & Managing Director |
| Mr. Kaushik Hanskumar Shah | WholeTime Director & CFO |
| Mr. Hemant Praful Shah | Whole Time Director |
| Mrs. Nehal Babu Karelia | Non Executive Director |
| Mr. Ketan Chandrakat Dave | Independent Director |
| Mrs. Kshama Dharnidharka | Independent Director |
FAQ
What is the intrinsic value of Hemant Surgical Industries Ltd?
Hemant Surgical Industries Ltd's intrinsic value (as of 13 January 2026) is ₹381.97 which is 31.71% higher the current market price of ₹290.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹378 Cr. market cap, FY2025-2026 high/low of ₹367/88.2, reserves of ₹110 Cr, and liabilities of ₹214 Cr.
What is the Market Cap of Hemant Surgical Industries Ltd?
The Market Cap of Hemant Surgical Industries Ltd is 378 Cr..
What is the current Stock Price of Hemant Surgical Industries Ltd as on 13 January 2026?
The current stock price of Hemant Surgical Industries Ltd as on 13 January 2026 is ₹290.
What is the High / Low of Hemant Surgical Industries Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Hemant Surgical Industries Ltd stocks is ₹367/88.2.
What is the Stock P/E of Hemant Surgical Industries Ltd?
The Stock P/E of Hemant Surgical Industries Ltd is 36.5.
What is the Book Value of Hemant Surgical Industries Ltd?
The Book Value of Hemant Surgical Industries Ltd is 94.3.
What is the Dividend Yield of Hemant Surgical Industries Ltd?
The Dividend Yield of Hemant Surgical Industries Ltd is 0.00 %.
What is the ROCE of Hemant Surgical Industries Ltd?
The ROCE of Hemant Surgical Industries Ltd is 16.4 %.
What is the ROE of Hemant Surgical Industries Ltd?
The ROE of Hemant Surgical Industries Ltd is 13.6 %.
What is the Face Value of Hemant Surgical Industries Ltd?
The Face Value of Hemant Surgical Industries Ltd is 10.0.